Pharmacyte Biotech Stock Market Value
| PMCB Stock | USD 0.90 0.02 2.27% |
| Symbol | PharmaCyte |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
PharmaCyte Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to PharmaCyte Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of PharmaCyte Biotech.
| 10/25/2025 |
| 01/23/2026 |
If you would invest 0.00 in PharmaCyte Biotech on October 25, 2025 and sell it all today you would earn a total of 0.00 from holding PharmaCyte Biotech or generate 0.0% return on investment in PharmaCyte Biotech over 90 days. PharmaCyte Biotech is related to or competes with Quoin Pharmaceuticals, NovaBay Pharmaceuticals, Alaunos Therapeutics, VivoSim Labs, Impact BioMedical, Pasithea Therapeutics, and Polyrizon. PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for canc... More
PharmaCyte Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure PharmaCyte Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess PharmaCyte Biotech upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.99 | |||
| Information Ratio | 0.0144 | |||
| Maximum Drawdown | 68.81 | |||
| Value At Risk | (7.87) | |||
| Potential Upside | 7.79 |
PharmaCyte Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for PharmaCyte Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as PharmaCyte Biotech's standard deviation. In reality, there are many statistical measures that can use PharmaCyte Biotech historical prices to predict the future PharmaCyte Biotech's volatility.| Risk Adjusted Performance | 0.0281 | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.96) | |||
| Sortino Ratio | 0.0225 | |||
| Treynor Ratio | 0.0788 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of PharmaCyte Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
PharmaCyte Biotech January 23, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0281 | |||
| Market Risk Adjusted Performance | 0.0888 | |||
| Mean Deviation | 4.53 | |||
| Semi Deviation | 4.96 | |||
| Downside Deviation | 5.99 | |||
| Coefficient Of Variation | 3909.61 | |||
| Standard Deviation | 9.33 | |||
| Variance | 87.01 | |||
| Information Ratio | 0.0144 | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.96) | |||
| Sortino Ratio | 0.0225 | |||
| Treynor Ratio | 0.0788 | |||
| Maximum Drawdown | 68.81 | |||
| Value At Risk | (7.87) | |||
| Potential Upside | 7.79 | |||
| Downside Variance | 35.92 | |||
| Semi Variance | 24.62 | |||
| Expected Short fall | (5.99) | |||
| Skewness | 4.06 | |||
| Kurtosis | 21.36 |
PharmaCyte Biotech Backtested Returns
PharmaCyte Biotech appears to be out of control, given 3 months investment horizon. PharmaCyte Biotech maintains Sharpe Ratio (i.e., Efficiency) of 0.0233, which implies the firm had a 0.0233 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for PharmaCyte Biotech, which you can use to evaluate the volatility of the company. Please evaluate PharmaCyte Biotech's Semi Deviation of 4.96, coefficient of variation of 3909.61, and Risk Adjusted Performance of 0.0281 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, PharmaCyte Biotech holds a performance score of 1. The company holds a Beta of 2.9, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, PharmaCyte Biotech will likely underperform. Please check PharmaCyte Biotech's treynor ratio, expected short fall, and the relationship between the jensen alpha and potential upside , to make a quick decision on whether PharmaCyte Biotech's historical price patterns will revert.
Auto-correlation | 0.37 |
Below average predictability
PharmaCyte Biotech has below average predictability. Overlapping area represents the amount of predictability between PharmaCyte Biotech time series from 25th of October 2025 to 9th of December 2025 and 9th of December 2025 to 23rd of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of PharmaCyte Biotech price movement. The serial correlation of 0.37 indicates that just about 37.0% of current PharmaCyte Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.37 | |
| Spearman Rank Test | -0.38 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PharmaCyte Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PharmaCyte Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacyte Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacyte Biotech Stock:Check out PharmaCyte Biotech Correlation, PharmaCyte Biotech Volatility and PharmaCyte Biotech Alpha and Beta module to complement your research on PharmaCyte Biotech. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
PharmaCyte Biotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.